Veliparib

ArtNr	HY-10129-100mg
Hersteller	MedChem Express
CAS-Nr.	912444-00-9
Menge	100 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 200 mg 25 mg 50 mg 5 mg
Kategorie	Food Safety Allergenes Neuroscience Neural Lineage Markers Inhibitors & Compound Libraries Small Molecules
Typ	Inhibitors
Specific against	other
Purity	99.77
Citations	[1]Donawho CK, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007 May 1;13(9):2728-37.\|[2]Du Y, et al. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med. 2016 Feb;22(2):194-201.\|[3]Liu F, et al. Effects of poly (ADP-ribose) polymerase-1 (PARP-1) inhibition on sulfur mustard-induced cutaneous injuries in vitro and in vivo. PeerJ. 2016 Apr 4;4:e1890. Acta Pharmacol Sin. 2022 Apr;43(4):781-787. Adv Sci (Weinh). 2025 Jul 16:e15585. Adv Sci (Weinh). 2025 Jun 25:e02448. Analyst. 2025 Dec 1;150(24):5501-5513. Biomed Res Int. 2023 Feb 6:2023:7891753. bioRxiv. 2025 Nov 4:2025.11.03.686423. BMC Cancer. 2022 Mar 23;22(1):312. Cancer Discov. 2017 Sep;7(9):984-998. Cancer Genet. 2019 Nov:239:26-32. Cancer Res. 2025 May 14. Cancers (Basel). 2024 Nov 5;16(22):3728. Cancers (Basel). 2024 Oct 10;16(20):3441. Cell Death Dis. 2024 Dec 18;15(12):914. Cell Signal. 2025 Jul:131:111709. Cells. 2021 Mar 9;10(3):599. Clin Cancer Res. 2017 Feb 15;23(4):1001-1011. Ecotoxicol Environ Saf. 2023 Mar 1:252:114630. EJNMMI Res. 2025 Apr 29;15(1):50. Front Mol Biosci. 2021 Apr 29:8:633344. Front Oncol. 2021 Jul 9:11:681441. Int J Biol Macromol. 2023 Jul 1;242(Pt 2):124794. J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Oct 1;1154:122195. J Invest Dermatol. 2024 May 30:S0022-202X(24)00384-1. J Mol Med (Berl). 2019 Aug;97(8):1183-1193. J Transl Med. 2024 Nov 26;22(1):1062. J Vet Med Sci. 2018 Nov 23;80(11):1775-1781. Mol Cancer Ther. 2019 Nov;18(11):2063-2073. Nanomaterials. 2021 Jun 8;11(6):1514. Nat Chem Biol. 2025 Jun 27. Nat Commun. 2021 Jun 24;12(1):3931. Nature. 2025 Sep;645(8082):1071-1080. Neoplasia. 2018 Mar 28;20(5):478-488. Neoplasia. 2025 May:63:101152. Neoplasia. 2019 Apr 24;21(6):533-544. Oncogene. 2022 Sep;41(37):4271-4281. Oncol Lett. 2025 Jan 7;29(3):128. Patent. US20180263995A1. Patent. US20180362972A1. Res Sq. 2024 Feb 21:rs.3.rs-3970470. Research Square Preprint. 2021 Feb. Research Square Preprint. 2024 Nov 06. Sci Signal. 2025 Oct 21;18(909):eadx2532. Theranostics. 2020 Jul 25;10(21):9477-9494. Electrostatics Joint Conference. 2016 July. Harvard Medical School LINCS LIBRARY Int J Curr Res Acad Rev. 2017; 5(3): 53-64. J Mol Med (Berl). 2019 Aug;97(8):1183-1193. Patent. US20200078369A1 Patent. US20200129476A1
Smiles	O=C(C1=C2NC([C@@]3(NCCC3)C)=NC2=CC=C1)N
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	ABT-888
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Category	Reference compound / Active compounds
Manufacturer - Targets	Autophagy; PARP
Manufacturer - HS Code	H302, H317
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	244298
Product Description	Veliparib (ABT-888) is a potent PARP inhibitor, inhibiting PARP1 and PARP2 with Kis of 5.2 and 2.9 nM, respectively[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO : ≥ 29 mg/mL
Manufacturer - Pathway	Autophagy; Cell Cycle/DNA Damage; Epigenetics
Clinical information	Phase 3
Isoform	PARP1; PARP2
UNSPSC Code	12352005
Precautionary	H302, H317

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.